Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results

Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results Eli Lilly reported positive Phase 3 results for its next-generation obesity drug, retatrutide, which delivered weight-loss results on par with those of bariatric surgery. In the TRIUMPH-1 trial, overweight adults, but without diabetes, achieved meaningful weight loss across all tested doses after 80 weeks: 12 mg dose: average weight loss of 70.3 pounds, or 28.3% of body weight. 9 mg dose: av...